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Abstract
Sudden cardiac death (SCD) accounts for 10–20% of total mortality, i.e., one in ﬁve individuals will eventually die suddenly.
Given the substantial genetic component of SCD in younger cases, postmortem genetic testing may be particularly useful in
elucidating etiological factors in the cause of death in this subset. The identiﬁcation of genes responsible for inherited cardiac
diseases have led to the organization of cardiogenetic consultations in many countries worldwide. Expert recommendations
are available, emphasizing the importance of genetic testing and appropriate information provision of affected individuals, as
well as their relatives. However, the context of postmortem genetic testing raises some particular ethical, legal, and practical
(including economic or ﬁnancial) challenges. The Public and Professional Policy Committee of the European Society of
Human Genetics (ESHG), together with international experts, developed recommendations on management of SCD after a
workshop sponsored by the Brocher Foundation and ESHG in November 2016. These recommendations have been endorsed
by the ESHG Board, the European Council of Legal Medicine, the European Society of Cardiology working group on
myocardial and pericardial diseases, the ERN GUARD-HEART, and the Association for European Cardiovascular
Pathology. They emphasize the importance of increasing the proportion of both medical and medicolegal autopsies and
educating the professionals. Multidisciplinary collaboration is of utmost importance. Public funding should be allocated to
reach these goals and allow public health evaluation.
Background
After sudden unexpected death (SUD), forensic or clinical
pathological examination may suggest an underlying cardiac
disorder, which can be hereditary. These deaths can then be
classiﬁed as cases of sudden cardiac death (SCD) [1, 2]. Taking
personal and family history into consideration is of crucial
importance and access to the related genetic information can be
relevant for medical reasons (for example, to identify the
possible cause(s) of death and then reﬁne the prevention stra-
tegies for surviving relatives), as well as for public health or
research purposes. Autopsy procedures are generally well
described in various European regulations [3, 4], however, they
often poorly incorporate postmortem genetic test information
into the autopsy ﬁndings [5], and procedures differ between
countries. The proportion of SUD in which autopsy takes place
also varies among countries. This lack of connection between
autopsies and genetic testing is highlighted by the increased
potential of new technologies in genetics, to shed light on
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genetic mechanisms in SCD. At the same time, new techniques
result in exponentially greater amounts of genetic data com-
pared with former tests, much of which cannot yet be inter-
preted, or have uncertain signiﬁcance. Distinguishing genetic
results of clinical utility from the uncertain output needs expert
interpretation and use of detailed phenotypic information.
Moreover, conducting genetic or genomic testing in the context
of postmortem DNA analysis raises practical, legal, and ethical
challenges; including issues around consent, conﬁdentiality and
dissemination of familial information.
To address the lack of coordination between different pro-
fessional domains and improve guidance on postmortem
genetic testing for cardiac disorders, the Public and Profes-
sional Policy Committee of the European Society of Human
Genetics (PPPC ESHG) organized a multidisciplinary Work-
shop sponsored by the Brocher Foundation and ESHG, on
23–25 November 2016. The workshop consisted of presenta-
tions by 12 experts in (forensic) pathology, cardiology, genet-
ics, ethics and law, and group work to identify common
challenges and draft recommendations. The workshop was
attended by members of the PPPC, invited experts, and parti-
cipants. After the workshop, a document listing recommenda-
tions was drafted, which was distributed among speakers and
participants of the workshop to solicit comments. The recom-
mendations were presented at several conferences in genetics
and cardiology. A core writing group was formed and an
updated draft was prepared for professional societies to discuss
according to their own procedures for membership or expert
consultation. The ESHG has posted this draft manuscript on its
website for membership consultation from the end of March
until April 30, 2018. After careful consideration of the sug-
gestions, relevant comments were integrated, and in June–July
2018 the document was endorsed by the Board of the European
Society of Human Genetics (ESHG), European Council of
Legal Medicine (ECLM), European Society of Cardiology
Working group on myocardial and pericardial diseases, Asso-
ciation for European Cardiovascular Pathology (AECVP), and
European Reference Network for Rare and Low Prevalence
Complex Diseases of the Heart (ERN GUARD-Heart).
Introduction
Sudden cardiac death (SCD) is a major public health pro-
blem. Based on studies in the USA, the Netherlands, Ireland
and China, SCD incidence ranges from 50 to 100 per
100,000 inhabitants annually and increases with age [6]. It
accounts for 10–20% of total mortality, i.e., one in 5–10
individuals will eventually die suddenly [7]. Among these
sudden death cases, the majority are SCDs [8]. For younger
persons (under 40 years of age), the incidence of sudden
death is lower, between 0.7 and 6.2/100,000 person-years
[9, 10], and in ± 70% of cases the cause is cardiac [10, 11].
SCD can be caused by a number of underlying cardiovas-
cular disorders. There are overall three categories: coronary
artery disease, cardiomyopathies and no causative pathology
(termed sudden arrhythmic death syndrome, SADS, if tox-
icology is performed, with no cause of death determined).
Coronary artery disease is the most common cause of death
in individuals over 35 years of age. Under the age of 35,
SADS is the most frequent cause of death. In younger per-
sons, genetically determined cardiac diseases (e.g., cardio-
myopathies, ion-channel diseases) account for an important
proportion of cases [1, 2, 10, 12–15]. Given the substantial
genetic component of SCD in younger cases, postmortem
genetic testing may be particularly useful in elucidating
etiological factors in the cause of death in this subset [12].
It is well acknowledged that the results of such autopsies,
including genetic testing, may be relevant for living blood
relatives and public health prevention strategies.1 The
identiﬁcation of genes responsible for cardiac diseases, such
as arrhythmic syndromes or cardiomyopathies, has led to
the organization of cardiogenetic consultations in many
countries worldwide. Expert recommendations are avail-
able, emphasizing the importance of genetic testing and
appropriate information provision of affected individuals as
well as their relatives [1, 13, 14, 16]. Furthermore, more
research on this topic is recommended [17]. The goal of this
paper is neither to review the speciﬁc clinical and patho-
logical aspects of genetic cardiac diseases nor the diagnostic
yield of genetic testing postmortem. However, the context
of postmortem genetic testing raises some particular ethical,
legal, and practical (including economic or ﬁnancial) chal-
lenges, which are the subject of this paper.
An important challenge stems from the fact that general
autopsy procedures are not always implemented and
autopsy rates for SUD differ with age, region, and country
[2, 10, 15]. A SUD most often will be investigated using
forensic procedures, focused on ascertaining whether the
cause of death is to be attributed to an underlying disease or
if there is any legal implication, thereby distinguishing
“natural” versus “unnatural” causes of SCD. Establishing
the precise deﬁnition of the disease and informing the
family members are not necessarily part of the aim of this
procedure. There are also practical barriers related to
organizational aspects, such as the lack of connection
between the judicial system and the medical system. So far,
it has been difﬁcult to establish an effective communication
between “postmortem professionals”, especially in the
context of the forensic setting (pathologists), and specia-
lized cardiogenetics experts. Insufﬁcient communication
1 In this document we will concentrate on cardiovascular disorders.
The resulting guidance may inspire efforts to integrate postmortem
genetic testing for other purposes. For instance, genetic susceptibility
to adverse drug reactions could be relevant both for forensic and public
health purposes.
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between different medical specialties (i.e., pathology, car-
diology, and genetics), further hinders the adequate provi-
sion of information to relatives of the deceased person [18].
Furthermore, there is a concern that medicolegal experts
(forensic pathologists and/or medical examiners) may not
have sufﬁcient training and/or resources (including time) to
properly interpret the genetic testing results [18, 19]. Clin-
ical genetic services focused on a cautious approach,
respectful of “the right-not-to-know”, when the clinical
utility of genetic testing was low or absent [20, 21]. As
genetic testing is increasingly able to identify conditions for
which there is surveillance, prevention or treatment, a
hypothetical right-not-to-know becomes more difﬁcult to
balance with a potential duty to warn [22–24]. Family
members of an index patient diagnosed with, or suspected
of, a heritable sudden cardiac death might not be aware of
the death of their relative and/or of the possibility of an
inherited genetic condition within the family, so that they
might not have the opportunity to proactively look for
appropriate advice and genetic information. A sudden car-
diac death clearly prevents the seeking of consent for
genetic testing and subsequent familial dissemination of
relevant information, adding to clinical paralysis about what
can legitimately be done with genetic ﬁndings in the
deceased. Limited communication among family members
and concerns about privacy might further complicate this.
Furthermore, there is a lack of international guidance about
the reporting of forensic postmortem genetic test results
with few local practice guidelines [18, 19, 25].
In the following paragraphs, we will summarize speciﬁc
procedural, ethical, legal, and practical challenges for post-
mortem genetic testing after sudden cardiac death that have
been discussed during the workshop. The key elements that
would ideally need to be addressed will be depicted in the
ﬂowchart (Fig. 1), though the actual organization of these
actions may vary between countries or jurisdictions. We
will conclude by making recommendations on how best to
include postmortem genetic testing in the context of SCD in
order to contribute to the identiﬁcation of the cause of death,
and then contribute to a better management of relatives by
optimizing screening strategies and the treatment of pre-
ventable disorders.
Sudden cardiac death
In this document, we will focus on cardiovascular dis-
orders. Sudden death (SD) “is a non-traumatic, unexpected
fatal event occurring within 1 h of the onset of symptoms in
an apparently healthy subject. If death is not witnessed, the
deﬁnition applies when the victim was in good health 24 h
before the event” [1]. The term sudden cardiac death (SCD)
“is used when a congenital, or acquired, potentially fatal
cardiac condition was known to be present during life; OR
autopsy has identiﬁed a cardiac or vascular anomaly as the
probable cause of the event; OR no obvious extra-cardiac
causes have been identiﬁed by postmortem examination
and therefore an arrhythmic event is a likely cause of
death” [1]. Knowing the cause of sudden death may be
particularly relevant for family members, (i) if the condi-
tion is hereditary and therefore relatives might also be at
risk, and (ii) if prevention or treatment is available.
Apparently healthy people who die while performing
sports, during sleep, while swimming, or while driving may
be victims of arrhythmias as a consequence of a cardio-
genetic condition. Some cardiogenetic conditions might be
identiﬁed in the course of the autopsy, e.g., in case of
myocardial disease, such as cardiomyopathies. However, a
number of cases remain unexplained after complete
autopsy including laboratory analyzes, referred to as sud-
den arrhythmic death syndrome (SADS), in which the
underlying mechanism of death might be an arrhythmia due
to an inherited ion-channel disorder [2, 13]. Our focus will
be on individuals over 1-year old, since implications rela-
ted to sudden infant death syndrome (SIDS) are somewhat
different and protocols for management—including infor-
mation for the family—are more clearly deﬁned. SIDS is
deﬁned as the unexpected death of a seemingly healthy
infant less than a year old with no cause of death deter-
mined after a full medicolegal investigation [1]. We,
however, acknowledge presumed SIDS cases might be
related to a genetic cause in up to 20% of cases (related to
inherited cardiac diseases, such as channelopathies or car-
diomyopathies) [26], but the proportion of explained cases
was less than 5% in recent studies [27], and alternative
non-cardiac monogenic causes may also occasionally be
responsible [28].
Postmortem investigations in different countries
How postmortem investigations are organized differs
between countries. For forensic purposes, the procedures in
place reﬂect the aim of investigating the potential involve-
ment of third parties (e.g., homicide or an accident) or self-
inﬂicted death, while for the medical context a different
system exists that aims to discover the underlying patho-
logical cause of unexpected death [2]. The ﬁrst is often
called “medicolegal autopsy”, the second “medical
autopsy”. For some of these contexts and in some countries,
autopsy may be mandated (e.g., in sudden infant death),
while for other situations relatives may be asked for per-
mission to perform autopsy, but this is not consistent across
Europe. Health insurance may end with a person’s death, so
funding for an autopsy and/or genetic testing may be a
major obstacle even when it may be of beneﬁt to surviving
relatives.
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Aim of a medicolegal autopsy
The traditional aim of a medicolegal autopsy is to ascertain
the cause of death in cases of unexpected, sudden death. If
homicide, suicide, or an accident can be ruled out, then a
“natural death” is assumed. Especially in younger cases,
“natural causes” may be related to underlying genetic
conditions, such as a cardiogenetic disorder. Given the
Fig. 1 Flowchart. MDT multidisciplinary team. *Mandatory if <40 y;
consider if >40 and <65y; Case by case >65 y; ¥Standards: minimal
criteria; histological examination; sampling for toxicology, genetics,
other lab tests; collection of health history/records. °Depending on the
country (judge, coroner,…)
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potential medical relevance of autopsy information for
family members, autopsies, including medicolegal autop-
sies, should have a dual aim of both ascertaining the cause
of death and providing information to family members in
case the ﬁndings indicate a substantial risk that family
members may also develop the disease.
Percentage of autopsies performed
There is considerable variation among countries and regions
in the numbers of autopsies conducted and for many countries
data are missing. In a study from the Netherlands, an autopsy
was found to be performed in about 43% of sudden deaths of
persons aged 1–44 years, in Denmark this has been found to
be 70% 1–35 and 60% 1–49 [10, 15, 29]. In many countries,
the rate is unknown. In the UK, in all cases of sudden
unexpected death a coroner is involved and an autopsy is
required. In some other countries medical professionals, such
as general practitioners may be primarily responsible for
establishing the cause of death and varied arrangements may
exist in different jurisdictions for requesting an autopsy,
whether medical or medicolegal. Even though in 1999, the
Committee of Ministers of the European Council adopted a
recommendation on the harmonization of medicolegal
autopsy rules and established clear criteria in what circum-
stances an autopsy is required [3, 4, 30], including sudden,
unexpected death, there is an urgent need to instruct the
relevant professionals regarding these criteria [2].
Need for a full autopsy
A full autopsy (i.e., including dissection of internal organs
in all body cavities, macroscopic and histologic examina-
tion of those organs, and utilizing modern postmortem
laboratory (toxicology, biochemistry, and microbiology)
tests, and storage of adequate samples for genetic testing) is
necessary to identify cases where a cardiac disorder is the
likely cause of death and to collect supporting evidence.
Procedural and technical guidance is available in a pub-
lished protocol [2], which should be implemented in all
European countries. This protocol provided by the Asso-
ciation for European Cardiovascular Pathology (AECVP)
includes a complete analysis of the heart. Funding may be a
major obstacle in increasing the number of autopsies where
postmortem investigation is not mandatory. In the UK, for
instance, all full autopsies are funded by the coroner, but
specialist cardiac examination is funded by the charity CRY
(Cardiac Risk in the Young; http://www.c-r-y.org.uk/). The
need for such an expert cardiac pathological opinion is
apparent, as referring pathologists tend to overcall structural
disease and underdiagnose SADS [31], while uncertain
ﬁndings at autopsy may still harbor genetic etiologies [32].
Moreover, the absence of a common protocol of
investigation and shared diagnostic criteria at postmortem
are main causes of the nonuniform reporting of the causes
of death among different series, and a clear example is
atherosclerotic coronary artery disease, which is under-
represented in many studies [2]. To allow for sufﬁcient
expertise and standard procedures, regional centers and/or
experts in examination of the heart would be ideal, as would
appropriate funding for the necessary investigations.
Genetic testing in relation to full autopsy
In many European countries, legal provisions do not allow
pathologists to request genetic testing after a full autopsy
including a thorough examination of the heart, and only
geneticists can order a genetic test. In the practice of for-
ensic autopsies, a genetic test can be requested for diag-
nostic purposes in some countries. However, the
interpretation of genetic test results for inherited cardiac
arrhythmia disorders requires highly specialized expertise
[33] and it may be difﬁcult, if not impossible, to use the test
as a diagnostic tool. If there is a clear indication for genetic
testing, for instance, in case of inherited cardiac disease,
such as cardiomyopathy, a panel of genes related to the
condition could be used. However, the indication for
genetic testing is more debated when the phenotype is
unclear (the autopsy is normal, unexplained SCD, SADS).
Clear pathogenic results may offer immediate beneﬁt to
families [34], but these form a minority of cases. Variants of
uncertain signiﬁcance (VUS) will be found in many cases,
and interpretation of the results would then require not only
phenotypic information of the deceased but also family
investigation to see whether the genotype segregates with a
cardiac phenotype. If variants are proven as de novo, then
this increases the potential utility. Otherwise, more exten-
sive testing is necessary. Often, at most an indication of the
possible diagnosis may be obtained but without conﬁrma-
tion. However, it has recently been shown that combining
postmortem testing and family investigation can lead to a
diagnostic yield of 40% [34, 35]. In practice, it may take too
long for the test results to be available for them to be
included in the ﬁnal autopsy report. Moreover, genetic
analysis currently remains expensive despite advances in
technology, and coroners may be reluctant to pay for
investigations that have no impact on the judicial procedure.
To allow for future genetic analysis, in the course of an
autopsy, a blood or tissue sample (spleen, muscle, skin, and
kidney) should be taken and stored frozen together with
detailed phenotypic information.
Storing samples for future genetic testing
If a DNA sample (or fresh frozen tissue from which DNA
could be extracted) is stored, it becomes possible to use the
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sample for testing in the future on family request, and
potentially for research. Consent for such DNA testing and
storage in clinical or biobank repositories is not a trivial
matter. Guidelines and legislation about who can or should
give such consent varies between countries. In the UK for
example, the Human Tissue Act recognizes that the spouse
of a deceased person—although often the person with
whom consent is discussed—does not have the same
interests in such storage as biologically related family
members. Refusal of consent for storage by a spouse could
deny blood relatives important information, and so should
only be accepted in case of an informed refusal and if there
is no one else who can provide relevant consent.
Sample storage requires stringent and good commu-
nication between the forensic pathologist and relevant
clinicians (e.g., geneticists or the cardiogenetic department).
Sample handling and storage should be part of standard
procedures. Currently, European recommendations exist
about the use of samples from a deceased person. In 2004, a
multidisciplinary expert group invited by the European
Commission published 25 recommendations on the ethical,
legal, and social implications of genetic testing [36]. The
24th recommendation addresses postmortem genetic ana-
lysis. It was stated that member states are to take action to
promote the right of access to samples and data from a
deceased person, in the case of the overriding interest of
blood relatives. However, in practice, forensic departments
often do not have the facilities to store material for a long
period of time. Long-term storage in clinical or biobanking
systems, and subsequent access by family members, raise
questions about what type of consent is appropriate.
Informing the family
After medicolegal autopsy, a report is sent to the repre-
sentative of the legal system (e.g., coroner, district attorney,
or police). However, whether and how the family is
involved in receiving the results of the autopsy differs
between countries. Even if information is provided to
family members about an underlying hereditary cardiovas-
cular disorder, it may not be clear to them whether this
might be relevant for their own health or how they can act
on the information by seeking appropriate referral. More
work to close the gap between medicolegal reporting about
the deceased and the appropriate care of relatives is
required. Examples include: establishing procedures for
providing “family letters” that provide clear information on
the possibility of a genetic disorder and where further
information and care can be obtained from; making clear
who is responsible for providing such information or letters;
having accessible online information and/or dedicated
medical professionals that can be contacted by families or
by their general practitioners. These procedures, however,
do not ensure that all relevant relatives will be reached.
Intrafamilial communication of genetic risk information is a
complex, multifaceted process, and ongoing support for the
communication with family members is often needed.
Family members also need to be informed when a medical
autopsy is performed if the results indicate the possibility of
an underlying hereditary cardiovascular problem. This
requires good communication and collaboration between,
most notably, the pathologist, the physician, and/or coroner
who ordered the postmortem investigation, the genetics
department and the general practitioner (family doctor).
Consent
In the context of a forensic investigation, explicit consent is
usually not required for postmortem investigations. It is
common practice to obtain consent from a patient to contact
family members during life, but this is obviously not pos-
sible after the patient’s death. Since relatives may have an
interest in knowing about the deceased’s results, and serious
harm might be prevented through their gaining this
knowledge, this is generally held to tip the balance in favor
of familial disclosure as opposed to any professional obli-
gation to maintain conﬁdentiality after death. However,
ethical debate continues [22, 23]. The communication of
relevant information is difﬁcult to standardize, but needs
careful balancing of relevant information in a clear manner
that allows relatives to make informed decisions about
whether or not they want to pursue investigations. Fur-
thermore deciding who is informed and when is not a trivial
task. Clinical Genetics Services have several tools in their
armoury to facilitate such familial communication, so early
contact or referral is recommended where possible.
Family investigation
The ﬁrst step in family investigation is a cardiology referral of
ﬁrst-degree family members, either in case of a clear autopsy
diagnosis of a cardiac disease that is usually inherited, or in
case of no clear cardiac disease diagnosed at autopsy. The
genetic investigations should be performed in the ﬁrst instance
on the deceased person’s sample as a general requirement
before any predictive testing in apparently healthy relatives.
The genetic analyzes are based on a targeted gene panel when a
clear cardiac disease has been identiﬁed at autopsy, or might be
enlarged to large gene panels or even exome sequencing in
case of SADS [34, 37, 38]. However, in the last situation
(when no clear cardiac disease is identiﬁed), the interpretation
of genetic results should be conducted with great caution and
can be considered as hypothesis generating rather than estab-
lishing the cause of death. Predictive genetic testing of relatives
can then be offered in cases where a variant affecting function
(or pathogenic variant according to the ACMG 2015 guidelines
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[39]) has been detected in the deceased and a reasonable link
with the death is made. When there are no genetic test results in
the deceased person but a cardiac disease is identiﬁed in a
relative after systematic screening, then genetic testing can be
performed in this particular relative. A careful consideration of
clinical information and investigations on the deceased and on
the relatives will be essential for a meaningful interpretation of
the genetic test results; it will often be wise for this to be
conducted as a multidisciplinary process.
Multidisciplinary collaboration
To connect the hitherto distinct ﬁelds of forensics, pathology,
genetics (clinical and laboratory, including bioinformatics
expertise), and cardiology, the establishment of multi-
disciplinary teams is vital. In many places, current collabora-
tions between cardiologists and geneticists can be the basis of
such teams. These multidisciplinary teams should ideally
include adult and pediatric cardiologists, geneticists, legal and
medical pathologists, and psychologists. Their roles are (i) to
examine individual cases to improve their management and
assist in evaluating and reevaluating whether the found genetic
variants (pathogenic or likely pathogenic variant) should be
used for investigation in the families; (ii) to share information
on management of samples, tests results, and family investi-
gations so as to enhance the overall management of each case
as well as to improve the practice and expertise of individual
professionals; (iii) to support professionals seeking advice; (iv)
to designate a case manager that can be contacted by healthcare
and forensic professionals as point of reference; (v) to con-
tribute to establishing local and national protocols and improve
their implementation; (vi) to collaborate with the relevant
institutions to collect and provide information about critical or
strategic matters for public health purposes.
Professionals and policy makers are encouraged to dis-
tribute and discuss the following recommendations to
improve practices relating to postmortem genetic testing for
cardiac disorders, and to stimulate the development of
national and European guidance. This task requires the
sustained and collaborative effort by the various profes-
sional groups involved.
Recommendations
1. Sudden cardiac death at a young age should be
considered as a public health priority because of the
high prevalence of inherited cardiac diseases and the
impact for the family. Therefore, public funding
should be allocated for related relevant investigations.
2. Increasing the proportion of both medicolegal and
medical autopsy in case of sudden, unexpected natural
death should be a major objective. This should be
mandatory for deaths under the age of 40, it should be
considered for deaths between ages 40 and 65, and
evaluated on a case by case basis after age 65.
3. Educate primary care physicians, coroners/district
attorneys, and (forensic) pathologists on when an
autopsy should be performed.
4. Medicolegal autopsies should have a dual aim: (i) to
establish if a death was natural or caused by a criminal
act or accident; (ii) to establish the cause of a natural
death and allow results to be used for preventive
healthcare for the surviving relatives.
5. In cases of sudden (cardiac) death, a full autopsy
should be performed, including heart dissection,
sampling for possible genetic and toxicological
analysis, and examination should adhere to minimal
standards as per European guidelines. Guidelines
should be made mandatory in European countries by
seeking support from Ministries of Health and Justice.
6. Access to second opinions of teams with expertise in
cardiovascular pathology (reference network) should
be promoted to support routine workup.
7. In the course of an autopsy, blood or tissue samples
(e.g., spleen, muscle, skin, and kidney) should be
taken and stored frozen together with detailed
phenotypic information for future genetic analysis in
the setting of a suspected inherited disorder or normal/
equivocal cardiac autopsy. This sample should be
accessible for medical purposes. After completion of
the forensic proceeding, the sample should be stored
in healthcare-embedded biobanks according to
national regulations. Family members should be
informed about the availability of the sample and
asked for consent to storage. It should be clear how
long a sample will be stored.
8. Organize multidisciplinary teams or reference centers
to connect different domains in healthcare and the
judiciary system in order to co-design pathways and
procedures, clarify who is responsible for storage
during and after the forensic investigation, clarify the
source of funding to implement this policy, design
information letters or leaﬂets for patients and family
members, and designate the case manager who can be
contacted by healthcare and forensic professionals as
a point of reference.
9. Information on genetic testing and communication of
genetic test results should be given in compliance with
standard procedures in clinical genetics and with the
appropriate national legislation. Familial communica-
tion and appropriate cascade testing should be
approached in a systematic fashion using genetic
services where possible. We consider that there can be
no duty to warn all relatives, but that a responsible
European recommendations integrating genetic testing into multidisciplinary management of sudden. . .
system will make attempts to alert relatives when
appropriate.
10. A multidisciplinary cardiogenetic team should con-
duct the family investigation. The appropriate genetic
test should be considered according to a combination
of pathology ﬁndings, family history, and the results
of cardiac family screening. The genetic test should be
performed on the DNA of the deceased in the ﬁrst
instance, and testing of relatives should then be
offered if a variant affecting function (pathogenic or
likely pathogenic variant) is identiﬁed.
11. Professionals, professional organizations, relevant
national institutions, and policy makers should make a
collaborative effort to further discuss the respective
responsibilities of the different professionals involved,
the allocation of funding for autopsies and postmortem
genetic tests, the procedures required to connect the
domains of forensics and healthcare in the context of
hereditary cardiac disorders identiﬁed in suddenly
deceased individuals, and how best to address the ethical
issues arising when informing family members and
possible psychological harms associated with disclosure.
12. There is a need for economic evidence and public health
evaluation to identify the incremental costs and con-
sequences of the use of genetic testing in postmortem
investigations compared with current practice to clarify
the situations for which postmortem genetic testing is an
effective use of ﬁnite budgets.
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